Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
“Company”), a specialty biopharmaceutical company commercializing
and developing therapeutics and diagnostic tests, today announced
its Annual General Meeting (“AGM”) will be held on May 15, 2020 at
10:00 a.m. ET. Due to the impact of the COVID-19 pandemic, the
meeting will be held virtually.
Shareholders will not be able to attend the AGM
in-person at a physical location. However, the platform for the
virtual AGM will provide shareholders as of the close of business
on April 1, 2020 the ability to listen to the AGM live, submit
questions and submit their vote during the meeting.
To be admitted to the virtual AGM, shareholders
need to visit www.virtualshareholdermeeting.com/AEZS2020 and enter
the control number included on the proxy form or voting instruction
form, as applicable. Online check-in will begin 15 minutes prior,
at 9:45 a.m. ET. The AGM will begin promptly at 10:00 a.m. ET on
May 15, 2020. If you are planning to attend the AGM, please refer
to and observe the “Rules of Conduct and Procedures” available
here.
Aeterna Zentaris strongly encourages its
shareholders to read its management proxy circular dated April 2,
2020 and other AGM materials carefully. If you are unable to attend
the AGM or if you wish to vote in advance of the AGM, please
carefully follow the instructions on the proxy or voting
instruction form. Shareholders that hold their common shares with a
bank, broker or financial intermediary that wish to vote at the AGM
must carefully follow the instructions provided by their
intermediary. In order to be effective, proxies must be received by
the Chair of the AGM no later than 48 hours (if voting by mail) or
24 hours (if voting by telephone or Internet) prior to the close of
business on the date of the AGM or any adjournment or postponement
thereof. The time limit for the deposit of proxies may be waived by
the Chair of the AGM without notice. If you are attending the AGM,
please log-on to the virtual meeting in advance to ensure that your
vote will be counted.
Even if shareholders intend to attend the
virtual AGM, it is strongly recommended that votes are made in
advance by telephone or Internet to ensure that votes are received
before the AGM. To cast your vote by telephone or Internet, please
have your proxy card or voting instruction form in hand and
carefully follow the instructions contained therein. Your telephone
or Internet vote authorizes the named proxies to vote your common
shares in the same manner as if you mark, sign and return your
proxy card. If shareholders of record vote by mail, your vote must
be received before 5:00 p.m. ET on May 13, 2020. If shareholders of
record vote by telephone or Internet, your vote must be received
before 5:00 p.m. ET on May 14, 2020.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
Macrilen™ (macimorelin), is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). Macrilen™ is currently
marketed in the United States through a license agreement with Novo
Nordisk and Aeterna Zentaris receives double-digit royalties on
sales. Aeterna Zentaris owns all rights to macimorelin outside of
the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of child-onset growth hormone deficiency (CGHD),
an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Europe and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company on
Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking
statements (as defined by applicable securities legislation) made
pursuant to the safe-harbor provision of the U.S. Securities
Litigation Reform Act of 1995, which reflect our current
expectations regarding future events. Forward-looking statements
include those relating to the intended use of proceeds and may
include, but are not limited to statements preceded by, followed
by, or that include the words "will," "expects," "believes,"
"intends," "would," "could," "may," "anticipates," and similar
terms that relate to future events, performance, or our results.
Forward-looking statements involve known and unknown risks and
uncertainties, including those discussed in this press release and
in our Annual Report on Form 20-F, under the caption "Key
Information - Risk Factors" filed with the relevant Canadian
securities regulatory authorities in lieu of an annual information
form and with the U.S. Securities and Exchange Commission. Known
and unknown risks and uncertainties could cause our actual results
to differ materially from those in forward-looking statements. Such
risks and uncertainties include, among others, our ability to raise
capital and obtain financing to continue our currently planned
operations, our ability to continue to list our Common Shares on
the NASDAQ, our ability to continue as a going concern is
dependent, in part, on our ability to transfer cash from Aeterna
Zentaris GmbH to Aeterna Zentaris and the U.S. subsidiary and
secure additional financing, our now heavy dependence on the
success of Macrilen™ (macimorelin) and related out-licensing
arrangements and the continued availability of funds and resources
to successfully commercialize the product, including our heavy
reliance on the success of the License Agreement with Novo, the
global instability due to the global pandemic of COVID-19, and its
unknown potential effect on our planned operations, including
studies, our ability to enter into out-licensing, development,
manufacturing, marketing and distribution agreements with other
pharmaceutical companies and keep such agreements in effect, our
reliance on third parties for the manufacturing and
commercialization of Macrilen™ (macimorelin), potential disputes
with third parties, leading to delays in or termination of the
manufacturing, development, out-licensing or commercialization of
our product candidates, or resulting in significant litigation or
arbitration, uncertainties related to the regulatory process,
unforeseen global instability, including the instability due to the
global pandemic of the novel coronavirus, our ability to
efficiently commercialize or out-license Macrilen™ (macimorelin),
our reliance on the success of the pediatric clinical trial in the
European Union (“E.U.”) and U.S. for Macrilen™ (macimorelin), the
degree of market acceptance of Macrilen™ (macimorelin), our ability
to obtain necessary approvals from the relevant regulatory
authorities to enable us to use the desired brand names for our
product, our ability to successfully negotiate pricing and
reimbursement in key markets in the E.U. for Macrilen™
(macimorelin), any evaluation of potential strategic alternatives
to maximize potential future growth and shareholder value may not
result in any such alternative being pursued, and even if pursued,
may not result in the anticipated benefits, our ability to take
advantage of business opportunities in the pharmaceutical industry,
our ability to protect our intellectual property, and the potential
of liability arising from shareholder lawsuits and general changes
in economic conditions. Investors should consult our quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties. Given these
uncertainties and risk factors, readers are cautioned not to place
undue reliance on these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce any
revisions to any of the forward-looking statements contained herein
to reflect future results, events or developments, unless required
to do so by a governmental authority or applicable law.
Investor Contact:
Jenene Thomas JTC Team T (US): +1 (833) 475-8247 E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024